Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-07 Combination Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
NCT07432022Phase 2Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of EMB-07 in B-cell non-Hodgkin lymphoma, sponsored by EpimAb Biotherapeutics. Started Apr 2026; status: recruiting.
02
Drugs
EMB-07
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07432022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432022.